Bert-Marcaz C, Fortanier E, Briantais A, Faucher B, Bourguiba R, Swiader L
J Neurol. 2025; 272(2):181.
PMID: 39891740
DOI: 10.1007/s00415-025-12902-x.
Ceccardi A, Dameri M, Ravera F, Gilardi N, Stabile M, Lombardo I
Br J Haematol. 2025; 206(2):758-762.
PMID: 39814683
PMC: 11829129.
DOI: 10.1111/bjh.19979.
Xing L, Liang W, Li Y, Xiao J, Li Z, Zhang F
Ann Hematol. 2024; .
PMID: 39613900
DOI: 10.1007/s00277-024-06107-x.
Alqatari S, Alqunais A, Alali S, Alharbi M, Hasan M, Al Shubbar M
J Clin Med. 2024; 13(22).
PMID: 39598114
PMC: 11594742.
DOI: 10.3390/jcm13226970.
Porges T, Rosenberg E, Wolach O, Sagy I, Sherf Y, Levi I
Ann Hematol. 2024; 103(12):5935-5939.
PMID: 39549055
DOI: 10.1007/s00277-024-06072-5.
Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS.
Li P, Alnoor F, Xie W, Williams M, Feusier J, Ding Y
Leukemia. 2024; 39(1):248-256.
PMID: 39516371
DOI: 10.1038/s41375-024-02397-2.
VEXAS without vacuoles: Linking genotype to phenotype.
Zhukovsky S, Rets A, Braaten T, Patel A
EJHaem. 2024; 5(5):981-986.
PMID: 39415928
PMC: 11474288.
DOI: 10.1002/jha2.1016.
Allogenic haematopoietic stem cell transplantation in VEXAS: A review of 33 patients.
Ali S, Gurnari C
Clin Rheumatol. 2024; 43(11):3565-3575.
PMID: 39347920
PMC: 11489273.
DOI: 10.1007/s10067-024-07160-7.
dysfunction in VEXAS and cancer.
Sakuma M, Haferlach T, Walter W
Oncotarget. 2024; 15:644-658.
PMID: 39347709
PMC: 11441413.
DOI: 10.18632/oncotarget.28646.
Navigating therapeutic challenges in VEXAS syndrome: exploring IL-6 and JAK inhibitors at the forefront.
Li X, Huang W, Yang X, Yang Q, Zheng Y, Huo Y
Mol Med. 2024; 30(1):152.
PMID: 39289602
PMC: 11409618.
DOI: 10.1186/s10020-024-00922-8.
Immune-dysregulation harnessing in myeloid neoplasms.
Sharifi M, Xu L, Nasiri N, Ashja-Arvan M, Soleimanzadeh H, Ganjalikhani-Hakemi M
Cancer Med. 2024; 13(17):e70152.
PMID: 39254117
PMC: 11386321.
DOI: 10.1002/cam4.70152.
A vexing case of a 73-year-old man with fevers, orbital cellulitis, and asymptomatic interstitial lung disease.
Agwan S, Zhang L, Baker T, Lane M, Godbolt D, Mackintosh J
Respirol Case Rep. 2024; 12(9):e70020.
PMID: 39253323
PMC: 11381310.
DOI: 10.1002/rcr2.70020.
A clinical phenotype of VEXAS syndrome with pleural effusion, infiltrates, and systemic inflammation in a 76-year-old patient: a case report.
Berger M, Schumacher F, Wollsching-Strobel M, Kroppen D, Stanzel S, Majorski D
J Med Case Rep. 2024; 18(1):392.
PMID: 39180090
PMC: 11344313.
DOI: 10.1186/s13256-024-04688-9.
Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome.
Dias A, Groarke E, Hickstein D, Patel B
Ann Hematol. 2024; 103(11):4427-4436.
PMID: 39168911
PMC: 11535077.
DOI: 10.1007/s00277-024-05942-2.
Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome.
Aalbers A, van Daele P, Dalm V, Valk P, Raaijmakers M
Hemasphere. 2024; 8(8):e129.
PMID: 39081801
PMC: 11287193.
DOI: 10.1002/hem3.129.
Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis.
Mohty R, Reljic T, Abdel-Razeq N, Jamy O, Badar T, Kumar A
Bone Marrow Transplant. 2024; 59(10):1423-1427.
PMID: 39060513
DOI: 10.1038/s41409-024-02375-3.
Update on ocular manifestations of the main monogenic and polygenic autoinflammatory diseases.
Fonollosa A, Carreno E, Vitale A, Jindal A, Ramanan A, Pelegrin L
Front Ophthalmol (Lausanne). 2024; 4:1337329.
PMID: 38984133
PMC: 11182141.
DOI: 10.3389/fopht.2024.1337329.
Patients with VEXAS diagnosed in a Danish tertiary rheumatology setting have highly elevated inflammatory markers, macrocytic anaemia and negative autoimmune biomarkers.
Rasch M, Szabados F, Jensen J, Nielsen K, Hauge E, Troldborg A
RMD Open. 2024; 8(2).
PMID: 38967099
PMC: 9462080.
DOI: 10.1136/rmdopen-2022-002492.
Thrombosis in Myeloid Malignancies: From CHIP to AML.
Borsellino B, Bravo-Perez C, Visconte V, Guarnera L
Cardiovasc Hematol Disord Drug Targets. 2024; 24(1):2-12.
PMID: 38879768
DOI: 10.2174/011871529X307253240530060107.
De-escalation of corticosteroids and clonal remission in mutation-driven VEXAS syndrome with 5-azacytidine.
Trikha R, Kong K, Galloway J, Basu T, Quek L, Wilson J
Haematologica. 2024; 109(10):3431-3434.
PMID: 38867587
PMC: 11446246.
DOI: 10.3324/haematol.2024.285519.
